Tech Transfer eNews Blog

Arizona State start-up advances novel antibody-based diagnostic technology

By Jesse Schwartz
Published: October 21st, 2020

Calviri, Inc., a start-up from Arizona State University (ASU), aims to commercialize a novel, antibody-based diagnostic platform in the U.S. and abroad.

Known as Immunosignature Technology, the platform uses hundreds of thousands of chemically diverse peptides, providing an unbiased profile of a person’s antibody repertoire. In studies, the technology has been applied to both infectious and chronic diseases to not only detect onset but also measure the severity of the disease and response to therapies.

“From a small volume of blood, we may be able to detect diseases such as cancer, Alzheimer’s and infections at early stages,” says Stephern Albert Johnston, inventor of the technology and CEO of Calviri. “A sensitive test for SARS-CoV-2 antibodies is also currently under development.”

Kathryn Sykes, vice president of research and product development at Calviri, comments, “Until now, we have focused on the early detection of cancers with our Frameshift Peptide Technology and treatment with pre-made vaccines. With the addition of the Immunosignature Technology we can expand our mission to other diseases.”

Skysong Innovations, the intellectual property management company for ASU, managed the licensing agreement with Calviri. Skysong’s senior vice president Kyle Siegal comments, “We are enthusiastic about Calviri and its ability to develop important commercial products with this promising, highly innovative ASU technology.”

Source: Tuscon

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment